Acute Invasive Aspergillosis
Treatment Market Drivers
Rising incidence of various types
of cancers, is in turn expected to support growth of the global Acute
Invasive Aspergillosis Treatment Market. According to the Centers for
Disease Control and Prevention, the epidemiology of invasive aspergillus
infection is dependent upon increasing number of solid organ transplants, stem
cell transplant, and newer immunosuppressive agents, 2017. According to Organ
Procurement and Transplantation Network (OPTN), around 8,500 organ transplants
have been performed in 2018 and the number is expected to grow in the near
future. These factors are expected to support the growth of the acute invasive
aspergillosis treatment market. Patients who undergo organ transplant procedure
are often prescribed immunosuppressant medications, which increases their
susceptibility to aspergillosis infection. Similarly, patients in the advanced
stages of AIDS are also highly susceptible to opportunistic infections such as
aspergillosis. According to the World Health Organization (WHO), around 36.7
million people were found suffering from HIV in 2016. Extended use of
corticosteroids further weakens the immune system, thus increasing the risk of
developing such infections. This in turn, is increasing the demand for acute
invasive aspergillosis treatment over the forecast period. According to British
Infection Association, the high risk population for invasive aspergillosis
includes patients who have undergone allogeneic hematopoietic stem cell
transplantation (HSCT), autologous HSCT patients, solid organ transplant
patients as well as AIDS patients, patients suffering from acute myeloid
leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia,
non-Hodgkin lymphoma, and myeloma patients. According to WHO, Cancer is the
second-leading cause of death globally, and the disease caused 8.8 million
deaths in 2015.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1520
Acute Invasive Aspergillosis is
an acute infection or fungal growth, which arises due to Aspergillus fungus.
Almost everyone comes in contact with the Aspergillus fungus as it is found on
decaying vegetation and dead leaves, however, not everyone is susceptible to
the infection. Aspergillosis is categorized into various types such as invasive
aspergillosis, chronic pulmonary aspergillosis, allergic bronchopulmonary
aspergillosis, allergic aspergillus sinusitis, aspergilloma, and cutaneous
aspergillosis. Active invasive aspergillosis (IA) is a rare, opportunistic, and
serious fungal infection, which affects immunocompromised patients or those
suffering from lung diseases. Risk factors responsible for the development of
invasive aspergillosis infection include weakened immune system, low white
blood cell count, presence of lung cavities, asthma or cystic fibrosis, and
long-term corticosteroid therapy. Commercially available drugs for the
treatment of aspergillus infection include Voriconazole, Capsofungin, and
Amphotericin B, among others.
The U.S. Food & Drug
Administration (FDA) is increasingly approving several drugs for the treatment
of this infection. For instance, Isavuconazonium, a prodrug form of
Isavuconazole was approved by the FDA in 2015. Astellas Pharma US, Inc. markets
Isavuconazonium under the brand name Cresemba. Astellas Pharma partnered with
Basilea Pharmaceutica International Ltd. for license, co-development, and
co-promotion of Isavuconazole (Cresemba), in 2010. In 2014, Basilea
Pharmaceutica International Ltd. received full rights to sell Isavuconazole in
all markets outside of the U.S. and Canada, and Astellas Pharma responsible for
U.S. and Canada markets. Moreover, Basilea Pharmaceutica Ltd. partnered with
Asahi Kasei Pharma for Isavuconazole development, licensing, and marketing in
Japan (responsibility of Asahi Kasei), in 2016. The global acute invasive
aspergillosis treatment market is expected to be significantly impacted over
the forecast period as the drug Cresemba will expire in 2020. As generic
manufacturers enter the market, the prices are expected to drop and volumes are
expected to increase over the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/acute-invasive-aspergillosis-treatment-market-1520
However, drug resistance to
antifungal medications is widely witnessed during treatment of aspergillosis
infections, which is expected to restrain growth of the acute invasive
aspergillosis treatment market over the forecast period.
Acute Invasive Aspergillosis
Treatment Market Insights
Most antifungal medications have
lost their patent protection over the last few years and generic versions of
these products are increasingly being made available by generic drug
manufacturers, which in turn is supporting growth of the acute invasive
aspergillosis treatment market. Manufacturers such as Amneal Pharmaceuticals,
Sandoz Inc., Glenmark Pharmaceuticals Ltd., Mylan Pharmaceuticals, Inc., and
Teva Pharmaceuticals offer generic versions of antifungal medications in the
acute invasive aspergillosis treatment market. Independent organizations are
dedicated towards research and development of novel antifungal therapies. For
instance, F2G, an established U.K.-based biotechnology company is focused on
the discovery and development of novel drugs for the treatment of serious
fungal diseases such as acute invasive aspergillosis.
Key players operating in the
global acute invasive aspergillosis treatment market include GlaxoSmithKline,
Mylan Pharmaceuticals, Inc., Novartis AG, Abbott laboratories, Eli Lilly and
Company, AstraZeneca Plc, Pfizer, Inc., Johnson & Johnson, Takeda
Pharmaceutical Company Ltd., Astellas, and Basilea Pharmaceutica International
Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1520
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment